Efficacy and Effectiveness of Antidepressants: Current Status of Research
The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
Background: This paper examines the current status of research on the efficacy and effectiveness of antidepressants. Methods: This paper reviews four meta-analyses of efficacy trials submitted to America’s Food and Drug Administration (FDA) and analyzes STAR*D (Sequenced Treatment Alternatives to Relieve Depression), the largest antidepressant effectiveness trial ever conducted. Results: Meta-analyses of FDA trials suggest that antidepressants are only marginally efficacious compared to placebos and document profound publication bias that inflates their apparent efficacy. These meta-analyses also document a second form of bias in which researchers fail to report the negative results for the pre-specified primary outcome measure submitted to the FDA, while highlighting in published studies positive results from a secondary or even a new measure as though it was their primary measure of interest. The STAR*D analysis found that the effectiveness of antidepressant therapies was probably even lower than the modest one reported by the study authors with an apparent progressively increasing dropout rate across each study phase. Conclusions: The reviewed findings argue for a reappraisal of the current recommended standard of care of depression.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the STAR-D trial, the largest naturalistic study of antidepressants so far conducted, the remission rate at one year for all participants taking antidepressants was 2.7% (108/4000), and 92.9% relapsed or dropped out (Pigott 2010).”
From Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults (2021) · cites this paper as Pigott 2010
In the citing paper
“Currently available antidepressant medications largely target monoamine pathways, but treatment of depression is only effective in about a third to a half of patients.1, 2”
From Association of depressive disorders, depression characteristics and antidepressant medication with inflammation (2012) · cites this paper as [1]
In the citing paper
“current treatment of depression is only effective in about a third to a half of patients,1, 2”
From Association of depressive disorders, depression characteristics and antidepressant medication with inflammation (2012) · cites this paper as [1]
In the citing paper
“In this study, 84 % of participants in this study answered in the affirmative to a question about whether they felt antidepressants had reduced their depression, a number well above that suggested by efficacy studies”
From ‘In my life antidepressants have been…’: a qualitative analysis of users’ diverse experiences with antidepressants (2016) · cites this paper as [26]
In the citing paper
“An understanding of users’ own experiences of antidepressant use is increasingly important in the context of growing doubts about the effectiveness of antidepressant treatment [5, 26], concerns about side effects [27] and withdrawal effects [28].”
From ‘In my life antidepressants have been…’: a qualitative analysis of users’ diverse experiences with antidepressants (2016) · cites this paper as [26]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879 · cited 1×
“recommendations for distinguishing between specific and nonspecific treatment effects, the first one being having an active placebo arm to reduce the likelihood of unblinding and thereby control the potential role of side effects in enhancing patients’ expectation of improvement. Real-World Effectiveness of Antidepres…”
BackgroundRush, A. J., Trivedi, M. H., Ibrahim, H. M., Carmody, T. J., Arnow, B., Klein, D. N., Markowitz, J. C., Ninan, P. T., Kornstein, S., Manber, R., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01866-8 · Cited by 3,829 · cited 1×
“p. 129] (table 2 ). 2 Table 2. Survival analysis by treatment step of patients who entered continuing care in remission T02 As mentioned earlier, STAR*D was designed to identify the best next-step treatment for the many patients who fail to get adequate relief from their initial SSRI trial. Due to the high study dropo…”
MethodKirsch, I., Deacon, B. J., Huedo-Medina, T. B., Scoboria, A., Moore, T. J., & Johnson, B. T. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050045 · Cited by 2,442
Selective publication of antidepressant trials and its influence on apparent efficacy
Turner, E. H., Matthews, A. M., Linardatos, E., Tell, R. A., & Rosenthal, R. (2008) · New England Journal of Medicine · doi:10.1056/nejmsa065779 · Cited by 2,435
HARKing: Hypothesizing after the results are known
Kerr, N. L. (1998) · Personality and Social Psychology Review · doi:10.1207/s15327957pspr0203_4 · Cited by 1,989
Chan, A.-W., Hróbjartsson, A., Haahr, M. T., Gøtzsche, P. C., & Altman, D. G. (2004) · JAMA · doi:10.1001/jama.291.20.2457 · Cited by 1,845
The Existence of Publication Bias and Risk Factors for Its Occurrence
Dickersin, K. (1990) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1990.03440100097014 · Cited by 1,417
Placebo Response in Studies of Major Depression: Variable, Substantial, and Growing
Walsh, B. T., Seidman, S. N., Sysko, R., & Gould, M. (2002) · JAMA · doi:10.1001/jama.287.14.1840 · Cited by 1,109 · cited 1×
“observed that early RCTs often enrolled hospitalized patients who were less responsive to placebo, whereas more recent trials typically enroll highly selected outpatients, contacted through mass media advertisements, who may be less severely depressed. In a meta-analysis of 75 RCTs published between 1981 and 2000, Wal…”
BackgroundSequenced treatment alternatives to relieve depression (STAR*D): Rationale and design
Rush, A. J., Fava, M., Wisniewski, S. R., Lavori, P. W., Trivedi, M. H., Sackeim, H. A., Thase, M. E., Nierenberg, A. A., Quitkin, F. M., Kashner, T. M., et al. (2004) · Controlled Clinical Trials · doi:10.1016/s0197-2456(03)00112-0 · Cited by 1,076 · cited 1×
“p. 739].The conclusion section of the research design article of STAR*D states: ‘STAR * D uses a randomized, controlled design to evaluate both the theoretical principles and clinical beliefs that currently guide the management of treatment-resistant depression in terms of symptoms, function, satisfaction, side-effect…”
Background
Research works printed but not linked: 9
- 10.1001%2Fjama.263.10.1385 · DOI
- 10.1176%2Fappi.ajp.163.7.1161 · doi:10.1176/appi.ajp.163.7.1161 · Paper page
- 10.1176%2Fappi.ajp.163.9.1519 · DOI · Paper page
- 10.1176%2Fappi.ajp.163.9.1531 · DOI
- 10.1176%2Fappi.ajp.163.11.1905 · doi:10.1176/appi.ajp.163.11.1905 · Paper page
- 10.1176%2Fappi.ajp.164.5.739 · DOI · Paper page
- 10.1001%2Fjama.287.13.1646 · DOI
- 10.1159%2F000235736 · DOI · Paper page
- 10.1016%2FS0895-4356%2899%2900161-4 · DOI · Paper page
Cited by
Fried, E. I., & Nesse, R. M. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.10.010 · Cited by 1,043
“…et al., 2013), the striking lack of progress in identifying biomarkers associated with depression diagnosis or treatment response (Hek et al., 2013; Kapur et al., 2012; Tansey et al., 2012), and the low efficacy of antidepressants in clinical trials (Kirsch et al., 2008; Pigott et al., 2010).”
Depression sum-scores don’t add up: why analyzing specific depression symptoms is essential
Fried, E. I., & Nesse, R. M. (2015) · BMC Medicine · doi:10.1186/s12916-015-0325-4 · Cited by 981
“Several large meta-analyses of clinical trials have demonstrated that antidepressants outperform placebos in less than half of the trials, and that clinically relevant improvements can be documented only for a minority of severely depressed patients [32-34].”
BackgroundThe Impact of Individual Depressive Symptoms on Impairment of Psychosocial Functioning
Fried, E. I., & Nesse, R. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0090311 · Cited by 424
Fried, E. I. (2015) · Frontiers in Psychology · doi:10.3389/fpsyg.2015.00309 · Cited by 367
“REVIEW published: 23 March 2015 doi: 10.3389/fpsyg.2015.00309 Edited by: Antoine Bechara, University of Southern California, USA Reviewed by: John Monterosso, University of Southern California, USA Richard McNally, Harvard University, USA *Correspondence: Eiko I. Fried, Research Group of Quantitative Psychology and In…”
BackgroundInfluentialMeta-review of depressive subtyping models
Harald, B., & Gordon, P. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.07.015 · Cited by 328
“Finally, and most importantly, the comparable efficacy of psychotherapies and antidepressant medication treatments (Baumeister et al., 2011, in press; Cuijpers et al., 2010; Ghaemi, 2008; Kirsch et al., 2008; Pigott et al., 2010; Turner et al., 2008) does not allow us to deduce specific treatment strategies for those…”
BackgroundVogelzangs, N., Duivis, H. E., Beekman, A. T. F., Kluft, C., Neuteboom, J., Hoogendijk, W., Smit, J. H., de Jonge, P., & Penninx, B. W. J. H. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.8 · Cited by 323
“only effective in about a third to a half of patients, 1,2 this indicates that new treatments are needed for specific subgroups.”
BackgroundBockting, C. L., Hollon, S. D., Jarrett, R. B., Kuyken, W., & Dobson, K. (2015) · Clinical Psychology Review · doi:10.1016/j.cpr.2015.02.003 · Cited by 295
Fried, E. I., Nesse, R. M., Zivin, K., Guille, C., & Sen, S. (2014) · Psychological Medicine · doi:10.1017/s0033291713002900 · Cited by 299
Undurraga, J., & Baldessarini, R. J. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.306 · Cited by 269
Genetic Contributions of Inflammation to Depression
Barnes, J., Mondelli, V., & Pariante, C. M. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.169 · Cited by 237
“Antidepressants can treat depression, but with varying efficacy (Pigott et al., 2010).”
Ferber, S. G., Namdar, D., Hen-Shoval, D., Eger, G., Koltai, H., Shoval, G., Shbiro, L., & Weller, A. (2020) · Current Neuropharmacology · doi:10.2174/1570159x17666190903103923 · Cited by 227
“Recent studies, including randomized controlled trials, indicate that certain phytocannabinoids produced by certain Cannabis sativa varieties have the potential to alleviate anxiety and other mental disorders [5-9].”
BackgroundBaumeister, H., Hutter, N., & Bengel, J. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008012.pub3 · Cited by 205
More treatment but no less depression: The treatment-prevalence paradox
Ormel, J., Hollon, S. D., Kessler, R. C., Cuijpers, P., & Monroe, S. M. (2022) · Clinical Psychology Review · doi:10.1016/j.cpr.2021.102111 · Cited by 213
Cytokine production capacity in depression and anxiety
Vogelzangs, N., de Jonge, P., Smit, J. H., Bahn, S., & Penninx, B. W. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.92 · Cited by 193
A systematic review of yoga for major depressive disorder
Cramer, H., Anheyer, D., Lauche, R., & Dobos, G. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.02.006 · Cited by 192
“But recent reviews found high dropout rates, low remission rates, and high placebo responses for these therapies (Mathew and Charney, 2009; Pigott et al., 2010; Rief et al., 2009; Turner et al., 2008); and complementary and alternative therapies can be a promising adjunct in the treatment of depression (Ravindran et a…”
BackgroundBaumeister, H., Hutter, N., & Bengel, J. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008381.pub2 · Cited by 188
Zou, L., Yeung, A., Li, C., Wei, G.-X., Chen, K. W., Kinser, P. A., Chan, J. S. M., & Ren, Z. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7080195 · Cited by 188
Uncoupling the dopamine D1-D2 receptor complex exerts antidepressant-like effects
Pei, L., Li, S., Wang, M., Diwan, M., Anisman, H., Fletcher, P. J., Nobrega, J. N., & Liu, F. (2010) · Nature Medicine · doi:10.1038/nm.2263 · Cited by 176
Making room for oxytocin in understanding depression
McQuaid, R. J., McInnis, O. A., Abizaid, A., & Anisman, H. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.07.005 · Cited by 174
The mechanisms of tolerance in antidepressant action
Fava, G. A., & Offidani, E. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.07.026 · Cited by 158
“The efficacy of antidepressants in treating depressive episodes has been well established in placebo controlled studies although the effect sizes for antidepressant treatment are only moderately larger than for placebo (Storosum et al., 2001; Turner et al., 2008; Bech, 2010; Pigott et al., 2010).”
Caldwell, Y. T., & Steffen, P. R. (2018) · International Journal of Psychophysiology · doi:10.1016/j.ijpsycho.2018.01.001 · Cited by 160
Fava, G. A., Rafanelli, C., Tomba, E., Guidi, J., & Grandi, S. (2011) · Psychotherapy and Psychosomatics · doi:10.1159/000321575 · Cited by 156
Squires, M., Tao, X., Elangovan, S., Gururajan, R., Zhou, X., Acharya, U. R., & Li, Y. (2023) · Brain Informatics · doi:10.1186/s40708-023-00188-6 · Cited by 222
Read, J., Cartwright, C., & Gibson, K. (2014) · Psychiatry Research · doi:10.1016/j.psychres.2014.01.042 · Cited by 150
“E-mail address: readj@liv.ac.uk (J. Read). sadness, personality changes, harmful effects on relationships, fear of addiction, and suicidality (Givens et al., 2006; Liebert and Gavey, 2008; Pestello and Davis-Berman, 2008; Price et al., 2009).”
BackgroundChronic mild stress paradigm as a rat model of depression: facts, artifacts, and future perspectives
Strekalova, T., Liu, Y., Kiselev, D., Khairuddin, S., Chiu, J. L. Y., Lam, J., Chan, Y.-S., Pavlov, D., Proshin, A., Lesch, K.-P., et al. (2022) · Psychopharmacology · doi:10.1007/s00213-021-05982-w · Cited by 141
“Despite a variety of therapeutic regimens available for depression, many of them appear to be effective in only about a half of patients, and up to 35% of MDD cases remain refractory to treatment (Munos 2009; Pigott et al. 2010; Insel and Sahakian 2012; Moeler 2017; Dubovsky 2018; Safer and Zito 2019).”
BackgroundVogelzangs, N., Beekman, A. T., van Reedt Dortland, A. K., Schoevers, R. A., Giltay, E. J., de Jonge, P., & Penninx, B. W. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.9 · Cited by 133
“Depression is a heterogeneous disorder and currently available treatments, including the prevention of relapse, is only effective in about a third to half of our patients (Pigott et al, 2010).”
BackgroundElectroencephalography-Derived Biomarkers of Antidepressant Response
Iosifescu, D. V. (2011) · Harvard Review of Psychiatry · doi:10.3109/10673229.2011.586549 · Cited by 129
Effect of probiotics on depressive symptoms: a meta-analysis of human studies
Goh, K. K., Liu, Y.-W., Kuo, P.-H., Chung, Y.-C. E., Lu, M.-L., & Chen, C.-H. (2019) · Psychiatry Research · doi:10.1016/j.psychres.2019.112568 · Cited by 123
Complementary therapies for clinical depression: an overview of systematic reviews
Haller, H., Anheyer, D., Cramer, H., & Dobos, G. J. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-028527 · Cited by 151
Primum Non Nocere: An Evolutionary Analysis of Whether Antidepressants Do More Harm than Good
Andrews, P. W., Thomson, J. A., Amstadter, A., & Neale, M. C. (2012) · Frontiers in Psychology · doi:10.3389/fpsyg.2012.00117 · Cited by 120
“Moreover, focusing on only those patients who completed all the treatment steps obscures the fact that 93% of the 1518 patients who met criteria for remission in one of the four steps either relapsed during 12 months of treatment or dropped out of the study (Pigott et al., 2010).”
BackgroundResultInfluentialBorrow, A. P., & Cameron, N. M. (2014) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2014.05.009 · Cited by 146
The neurobiology of treatment-resistant depression: A systematic review of neuroimaging studies
Runia, N., Yücel, D. E., Lok, A., de Jong, K., Denys, D. A. J. P., van Wingen, G. A., & Bergfeld, I. O. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.12.008 · Cited by 117
“Due to issues like publication bias, failure to report negative results for pre-specified primary outcome measures, and patient selection, remission rates for antidepressant therapies may be inflated (Pigott et al., 2010).”
mGlu2/3 and mGlu5 receptors: Potential targets for novel antidepressants
Chaki, S., Ago, Y., Palucha-Paniewiera, A., Matrisciano, F., & Pilc, A. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.05.022 · Cited by 116
“Importantly, meta- analyses suggest that antidepressants are only marginally efficacious compared to placebos, especially at moderate levels of initial depression (Kirsch et al., 2008; Pigott et al., 2010).”
Psychedelic microdosing: a subreddit analysis
Lea, T., Amada, N., & Jungaberle, H. (2020) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2019.1683260 · Cited by 115
“Indeed, variable health outcomes from psychiatric medications have been well documented (Leucht et al. 2017; Pigott et al. 2010).”
BackgroundBaumeister, H., Hutter, N., & Bengel, J. (2014) · Diabetic Medicine · doi:10.1111/dme.12452 · Cited by 113
Lin, I.-M., Fan, S.-Y., Yen, C.-F., Yeh, Y.-C., Tang, T.-C., Huang, M.-F., Liu, T.-L., Wang, P.-W., Lin, H.-C., Tsai, H.-Y., et al. (2019) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2019.17.2.222 · Cited by 109
Evidence for alterations of the glial syncytial function in major depressive disorder
Medina, A., Watson, S. J., Bunney, W., Myers, R. M., Schatzberg, A., Barchas, J., Akil, H., & Thompson, R. C. (2016) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2015.10.010 · Cited by 108
“For example, current antidepressant therapies are largely based on the use of monoaminergic-related compounds, but the overall treatment efficacy remains controversial, and may be as low as 25% (Pigott et al., 2010).”
BackgroundKinser, P. A., Bourguignon, C., Whaley, D., Hauenstein, E., & Taylor, A. G. (2013) · Archives of Psychiatric Nursing · doi:10.1016/j.apnu.2013.01.003 · Cited by 105
Ormel (2019) · doi:10.1097/yco.0000000000000505 · Cited by 102
Jaworska, N., de la Salle, S., Ibrahim, M.-H., Blier, P., & Knott, V. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00768 · Cited by 99
“…patients found that fewer than ∼ 50% responded ( > 50% symptom decreases), and only ∼ 30% remitted (absence/near absence of symptoms), to intervention with a serotonin reuptake inhibitor (SSRI) antidepressant (6, 7); SSRIs are the most common antidepressant pharmacotherapy for treating MDD.”
BackgroundBaumeister, H. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.05.025 · Cited by 97
“, 2011) only remained true for severely depressed patients, when data of unpublished trials were taken into account (Fournier et al., 2010; Kirsch et al., 2008; Pigott et al., 2010; Turner et al., 2008).”
BackgroundVan Leeuwen, E., van Driel, M. L., Horowitz, M. A., Kendrick, T., Donald, M., De Sutter, A. I., Robertson, L., & Christiaens, T. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013495.pub2 · Cited by 90
Pigott, H. E. (2015) · The Canadian Journal of Psychiatry · doi:10.1177/070674371506000104 · Cited by 93
Self-citationPigott, H. E., Kim, T., Xu, C., Kirsch, I., & Amsterdam, J. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-063095 · Cited by 93
Self-citationTreatment-resistant major depressive disorder and assisted dying
Schuklenk, U., & Vathorst, S. V. D. (2015) · Journal of Medical Ethics · doi:10.1136/medethics-2014-102458 · Cited by 93
Chiesa, A., Castagner, V., Andrisano, C., Serretti, A., Mandelli, L., Porcelli, S., & Giommi, F. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2015.02.003 · Cited by 89
“Indeed, a large proportion of patients does not achieve full symptom remission, even following several treatment steps of medications and/or psychotherapy (Rush et al., 2006; Pigott et al., 2010; Aguglia et al., 2014).”
BackgroundInfluentialThe differential influence of life stress on individual symptoms of depression
Fried, E. I., Nesse, R. M., Guille, C., & Sen, S. (2015) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12395 · Cited by 89
“This covert heterogeneity may help to explain recent ‘disappointing’ findings such as low reliability for MDD diagnoses in the DSM-5 field trials (34), low antidepressant efficacy compared with placebo response (35), lack of common genetic markers associated with antidepressant response (36) and failure to detect even…”
BackgroundClevenger, S. S., Malhotra, D., Dang, J., Vanle, B., & IsHak, W. W. (2018) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125317737264 · Cited by 83
Cohen, S. E., Zantvoord, J. B., Wezenberg, B. N., Bockting, C., & van Wingen, G. A. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01286-x · Cited by 93
Cross-sectional networks of depressive symptoms before and after antidepressant medication treatment
Bos, F. M., Fried, E. I., Hollon, S. D., Bringmann, L. F., Dimidjian, S., DeRubeis, R. J., & Bockting, C. L. H. (2018) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-018-1506-1 · Cited by 78
“Given that there is a substantial proportion of patients who do not seem to benefit from acute antidepressant treatment [6], Electronic supplementary material The online version of this article (https ://doi.”
BackgroundThe Clinical Interview for Depression: A Comprehensive Review of Studies and Clinimetric Properties
Guidi, J., Fava, G. A., Bech, P., & Paykel, E. (2011) · Psychotherapy and Psychosomatics · doi:10.1159/000317532 · Cited by 79
Pretty, J., & Barton, J. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17217769 · Cited by 78
“These efficacy rates are better than most reported uses of antidepressants [69,70].”
BackgroundMindfulness-based yoga intervention for women with depression
Schuver, K. J., & Lewis, B. A. (2016) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2016.03.003 · Cited by 77
Antidepressant use and new‐onset diabetes: a systematic review and meta‐analysis
Bhattacharjee, S., Bhattacharya, R., Kelley, G. A., & Sambamoorthi, U. (2013) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2393 · Cited by 77
“The Sequenced Treatment Alternatives to Relieve Depression trial, the largest antidepressant effectiveness trial ever conducted, showed less than modest remission rates [42].”
Heart and soul: heart rate variability and major depression
Kidwell, M., & Ellenbroek, B. A. (2018) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000387 · Cited by 86
“Although this approach has been useful in the development of pharmaceutical interventions, their effectiveness remains relatively low (Pigott et al., 2010; Locher et al., 2017), and the delayed onset of effectiveness is linked to several significant limitations, including increased suicidality in initial stages of tre…”
BackgroundHelgadóttir, B., Forsell, Y., Hallgren, M. Å., Möller, J., & Ekblom, Ö. B. (2017) · Preventive Medicine · doi:10.1016/j.ypmed.2017.08.008 · Cited by 96
Effects of cannabidiol in males and females in two different rat models of depression
Shbiro, L., Hen-Shoval, D., Hazut, N., Rapps, K., Dar, S., Zalsman, G., Mechoulam, R., Weller, A., & Shoval, G. (2018) · Physiology & Behavior · doi:10.1016/j.physbeh.2018.12.019 · Cited by 81
Tundo, A., de Filippis, R., & Crescenzo, F. D. (2019) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13055 · Cited by 82
Hengartner, M. P. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320921694 · Cited by 72
Quah-Smith, I., Smith, C., Crawford, J. D., & Russell, J. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.11.058 · Cited by 72
“There was also concern that, for those who continued pharmacotherapy, the adverse effects actually increased the placebo response (Pigott et al., 2010).”
BackgroundTardive dysphoria: The role of long term antidepressant use in-inducing chronic depression
El‐Mallakh, R. S., Gao, Y., & Roberts, R. J. (2011) · Medical Hypotheses · doi:10.1016/j.mehy.2011.01.020 · Cited by 81
Schmauss, C. (2015) · Scientific Reports · doi:10.1038/srep08171 · Cited by 70
A meta-analysis of lipid peroxidation markers in major depression
Lanctot, K. L., Mazereeuw, G., Herrmann, N., Andreazza, A., & Khan, M. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s89922 · Cited by 69
“Treatment of MDD with selective serotonin or norepinephrine reuptake inhibitors or other currently available antidepressants is modestly effective (response rates of 26%–63%);(4,5) however, relapse frequently occurs and several antidepressant trials may be needed in order for symptom remission to be achieved.(4,5) As…”
Multicriteria benefit–risk assessment using network meta-analysis
van Valkenhoef, G., Tervonen, T., Zhao, J., de Brock, B., Hillege, H. L., & Postmus, D. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2011.09.005 · Cited by 68
“This is even more important in the light of recent doubt on the efficacy of antidepressants [16].”
BackgroundA Review of the Conceptualisation and Risk Factors Associated with Treatment-Resistant Depression
Murphy, J. A., Sarris, J., & Byrne, G. J. (2017) · Depression Research and Treatment · doi:10.1155/2017/4176825 · Cited by 67
“There are long-standing concerns about publication biases which inflate the perceived efficacy of antidepressants in RCTs and inadvertently influence evidence-based care for individuals with depression [3, 4].”
BackgroundTully, P. J., Ang, S. Y., Lee, E. J., Bendig, E., Bauereiß, N., Bengel, J., & Baumeister, H. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008012.pub4 · Cited by 64
“Another bias results from selective reporting of negative findings for prespecified primary outcomes while emphasizing positive results from secondary or new outcomes of antidepressant medication trials (Pigott 2010).”
Backgroundvan der Lem, R., van der Wee, N. J. A., van Veen, T., & Zitman, F. G. (2012) · Psychotherapy and Psychosomatics · doi:10.1159/000330890 · Cited by 63
Morbidity in depressive disorders
Baldessarini, R. J., Forte, A., Selle, V., Sim, K., Tondo, L., Undurraga, J., & Vázquez, G. H. (2017) · Psychotherapy and Psychosomatics · doi:10.1159/000448661 · Cited by 63
Distress tolerance and symptoms of depression: A review and integration of literatures
Lass, A. N. S., & Winer, E. S. (2020) · Clinical Psychology: Science and Practice · doi:10.1111/cpsp.12336 · Cited by 62
Dembo, J., Schuklenk, U., & Reggler, J. (2018) · The Canadian Journal of Psychiatry · doi:10.1177/0706743718766055 · Cited by 60
“Mental illness can certainly be irremediable.(27,28,29,30) In the case of major depression, the STAR*D study conducted by the National Institute of Mental Health (NIMH), indicated that 30% or more of patients did not respond to multiple sequential medication trials, and of those who did respond, up to 70% relapsed wit…”
BackgroundHenderson, T. A., & Morries, L. D. (2017) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2017.00187 · Cited by 60
“For example, the STAR-D trials examined antidepressant response in patients unresponsive to a first trial of serotonergic antidepressant and achieved only a 13% response rate after a sequence of four different antidepressants with multiple mechanisms of action (2, 3).”
BackgroundInfluentialFried, E. I., Boschloo, L., van Borkulo, C. D., Schoevers, R. A., Romeijn, J.-W., Wichers, M., de Jonge, P., Nesse, R. M., Tuerlinckx, F., & Borsboom, D. (2015) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2015.00117 · Cited by 59
“A treatment focus on especially prevalent and central symptoms, instead of the categori-cally defined and heterogeneous disorders itself, may help increase the currently disappointing levels of treatment response (20).”
The failure of the antidepressant drug discovery process is systemic
Hendrie, C., & Pickles, A. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881112466185 · Cited by 59
Why REM sleep? Clues beyond the laboratory in a more challenging world
Horne, J. (2012) · Biological Psychology · doi:10.1016/j.biopsycho.2012.10.010 · Cited by 70
Macaques Exhibit a Naturally-Occurring Depression Similar to Humans
Xu, F., Wu, Q., Xie, L., Gong, W., Zhang, J., Zheng, P., Zhou, Q., Ji, Y., Wang, T., Li, X., et al. (2015) · Scientific Reports · doi:10.1038/srep09220 · Cited by 59
Bech, P. (2010) · Psychotherapy and Psychosomatics · doi:10.1159/000320118 · Cited by 56
Circulating metabolites modulated by diet are associated with depression
van der Spek, A., Stewart, I. D., Kühnel, B., Pietzner, M., Alshehri, T., Gauß, K. F., Hysi, P. G., MahmoudianDehkordi, S., Heinken, A., Luik, A. I., et al. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02180-2 · Cited by 74
Berlim, M. T., Richard‐Devantoy, S., dos Santos, N. R., & Turecki, G. (2020) · Psychological Medicine · doi:10.1017/s0033291720001002 · Cited by 65
Möller, H.-J., Bitter, I., Bobes, J., Fountoulakis, K., Höschl, C., & Kasper, S. (2012) · European Psychiatry · doi:10.1016/j.eurpsy.2011.08.002 · Cited by 53
“Amongst others, the issue of clinically relevant efficacy [87,147], as well as the question of whether antidepressants are safe in terms of suicidality, are addressed [34,53].”
BackgroundHengartner, M. P. (2017) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2017.00275 · Cited by 52
“Finally, according to the re-analysis of STAR*D (54), only 5.”
BackgroundMethodInfluentialLieblich, S. M., Castle, D. J., Pantelis, C., Hopwood, M., Young, A. H., & Everall, I. P. (2015) · BJPsych Open · doi:10.1192/bjpo.bp.115.000786 · Cited by 52
The use of referenced-EEG (rEEG) in assisting medication selection for the treatment of depression
DeBattista, C., Kinrys, G., Hoffman, D. A., Goldstein, C., Zajecka, J., Kocsis, J. H., Teicher, M. H., Potkin, S. G., Preda, A., Multani, G., et al. (2010) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2010.05.009 · Cited by 52
Guo, L., Kong, Z., & Zhang, Y. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16050826 · Cited by 46
Gibson, K., Cartwright, C., & Read, J. (2016) · BMC Psychiatry · doi:10.1186/s12888-016-0844-3 · Cited by 43
“sant treatment [5, 26], concerns about side effects [27]”
BackgroundStassen, H. H., Bachmann, S., Bridler, R., Cattapan, K., Herzig, D., Schneeberger, A. R., & Seifritz, E. (2021) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-021-01358-5 · Cited by 54
Bockting, C., Smid, N. H., Koeter, M. W. J., Spinhoven, P., Beck, A. T., & Schene, A. H. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.06.048 · Cited by 56
“…with ADs during the acute phase only, does not have an enduring effect in preventing recurrence (Geddes et al., 2003; Kaymaz et al., 2008; Hansen et al., 2008; Glue et al., 2010; Vittengl et al., 2007; Guidi et al., 2010; Oestergaard and Møldrup, 2011; Imel et al., 2008; Pigott et al., 2010).”
Patient-Centered Perspectives on Antidepressant Use: A Narrative Review
Gibson, K., Cartwright, C., & Read, J. (2014) · International Journal of Mental Health · doi:10.2753/imh0020-7411430105 · Cited by 46
“While antidepressants have become a mainstay of depression treatment at primary care, researchers have raised concerns about whether they are being prescribed well in excess of need [8, 9] and also about their efficacy for the treatment of mild to moderate depression [10, 11].”
BackgroundWright, J. S., & Panksepp, J. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2011.08.004 · Cited by 49
Walach, H., & Loef, M. (2015) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2015.03.027 · Cited by 55
“Sequenced Treatment Alternatives to Relieve Depression (STAR*D), a large outcomes study in realistic patient groups, found that 1-year remission rates are maximally 43% [26], more likely 38%, approaching what can be expected from a placebo effect [27], well below the usefulness expected from theory and trials [28].”
BackgroundFuxe, K., & Borroto-Escuela, D. O. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.1074175 · Cited by 43
“Nevertheless, 30% of the depressed patients remain treatment resistant [31] and the antidepressant drugs acting on monoamine neurons are only weakly more active than placebo [32].”
BackgroundHengartner, M. P., Angst, J., & Rössler, W. (2018) · Psychotherapy and Psychosomatics · doi:10.1159/000488802 · Cited by 42
How 'evidence-based' is the Movement for Global Mental Health?
Ingleby, D. (2014) · UvA-DARE (University of Amsterdam) · Cited by 64
Overprescribed Medications for US Adults: Four Major Examples
Safer, D. J. (2019) · Journal of Clinical Medicine Research · doi:10.14740/jocmr3906 · Cited by 46
Antidepressant combination for major depression in incomplete responders—a systematic review
Rocha, F. L., Fuzikawa, C., Riera, R., Ramos, M. G., & Hara, C. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.04.048 · Cited by 40
“A review of four meta-analyses of efficacy trials submitted to the US Food and Drug Administration (FDA) suggests that antidepressants are only marginally efficacious compared with placebo and documents a profound publication bias that inflates their apparent efficacy (Pigott et al., 2010).”
BackgroundAlternating current cranial electrotherapy stimulation (CES) for depression
Kavirajan, H., Lueck, K., & Chuang, K. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010521.pub2 · Cited by 43
Quantitative Electroencephalography in Guiding Treatment of Major Depression
Schiller, M. J. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00779 · Cited by 45
Beliefs of people taking antidepressants about the causes of their own depression
Read, J., Cartwright, C., Gibson, K., Shiels, C., & Magliano, L. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.11.009 · Cited by 37
“These increases occur despite evidence that their efficacy was initially overestimated (Kirsch et al., 2008; Pigott et al., 2010) and their adverse effects minimised.”
BackgroundRole of the Axonal Initial Segment in Psychiatric Disorders: Function, Dysfunction, and Intervention
Hsu, J. W.-C., Nilsson, C. L., & Laezza, F. (2014) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2014.00109 · Cited by 43
Morozova, A. Y., Zubkov, E. A., Strekalova, T. V., Kekelidze, Z. I., Storozeva, Z., Schroeter, C. A., Bazhenova, N., Lesch, K., Cline, B. H., & Chekhonin, V. P. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2016.03.003 · Cited by 44
“Therefore, the failure to discover new antidepressants with improved efficacy and concerns over the clinical utility of recently developed drugs has raised important questions regarding the validation of preclinical studies (Pigott et al., 2010; Hoffman, 2013).”
BackgroundNakajima, S., Uchida, H., Suzuki, T., Watanabe, K., Hirano, J., Yagihashi, T., Takeuchi, H., Abe, T., Kashima, H., & Mimura, M. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2011.08.008 · Cited by 40
Metadata
- Authors
- Pigott, H. E., Leventhal, A. M., Alter, G. S., & Boren, J. J.
- Affiliations
- American University (US)
- ORCID
- Pigott, H. Edmund
- Venue
- Psychotherapy and Psychosomatics
- Publisher
- S. Karger AG
- Published
- 2010
- Volume
- 79
- Issue
- 5
- Pages
- 267-279
- ISSN
- 0033-3190 (ISSN-L)
- 1423-0348
- OpenAlex
- W2020265264
- Cited by
- 347
- References
- 58
- Citations by year
- 2026: 10 · 2025: 16 · 2024: 15 · 2023: 21 · 2022: 13 · 2021: 23 · 2020: 18 · 2019: 22 · 2018: 22 · 2017: 16 · 2016: 19 · 2015: 42 · 2014: 22 · 2013: 20 · 2012: 26
- FWCI
- 3.20
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Psychotherapy and Psychosomatics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Keywords
- antidepressants, depression, antidepressant efficacy, publication bias, STAR*D trial, meta-analysis, selective outcome reporting, dropout rates
- MeSH terms
- Antidepressive Agents, Depressive Disorder, Humans, Meta-Analysis as Topic, Randomized Controlled Trials as Topic, Treatment Outcome, Publication Bias, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.